OAE

OAE Publishing Inc.

OPEN ACCESS

ISSN: 2578-532X (Online)

Cancer Drug Resistance

www.oaepublish.com

Annual Progress Report 2023

INTERNATIONAL, PEER-REVIEWED, OPEN ACCESS, ONLINE JOURNAL

@cdrjournal

Contents

I. Geographical Breakdown of Authors

Submitted papers in 2023

Accepted papers in 2023

Legend:
- USA and Canada
- Europe
- China
- India
- Japan
- South America
- Rest of Asia
- Others

Submitted papers in 2023: 20%, 28%, 23%, 14%, 5%, 2%, 5%, 3%

Accepted papers in 2023: 34%, 38%, 6%, 4%, 2%, 4%, 8%, 4%

- In the investigation of cancer drug resistance as the focal point within the Web of Science database, a search for highly cited articles in the past five years was conducted. The analysis of the results reveals that the most influential articles in this domain emanate from research conducted in the United States, China, the United Kingdom, Italy, Germany, France, Spain, Canada, Australia, and South Korea.

- Despite receiving 28% of the submitted manuscripts from European countries, **it is noteworthy that there has been a relative scarcity of contributions from prominent European nations such as the United Kingdom, Germany, France, and Spain. Furthermore, Canada, Australia, and South Korea have exhibited a comparable shortfall in manuscript submissions.**

- It is our aspiration for the upcoming year, 2024, to witness an augmentation in the number of submitted and subsequently published manuscripts from these aforementioned countries. The objective is to foster greater inclusivity and representation within the journal, thereby enriching the diversity of perspectives and insights shared in the field of cancer drug resistance.

II. Online Usage

2.1 Online Usage

2.2 Geographical Breakdown of Readers

2.1 Online Usage

Website Data in 2023													
	Jan.	Feb.	Mar.	Apr.	May	Jun.	Jul.	Aug.	Sep.	Oct.	Nov.	Dec.	Total
Website visitors	13055	14736	12609	12649	12678	11040	9021	10037	10975	5507	11540	10298	134,145
Webpage views	22034	26324	24702	29637	27059	23306	15044	22367	19152	10050	15469	14378	249,522
Full text article downloads	8261	6604	6761	6759	5205	11025	14095	12215	12821	20166	19834	18745	142491

- In order to provide a smoother and faster journal browsing experience, the website in general was revamped and updated in October 2023, and the new site is correspondingly faster. Some data was lost during the changeover, which explains the drop in data for October.

- Webpage views reflect an average of multiple pages visited per visitor, **indicating that they are exploring content in depth or accessing multiple articles of great interest to the journal.**

2.2 Geographical Breakdown of Readers

Legend:
- USA
- China
- UK
- India
- Australia
- Canada
- Italy
- South Korea
- Japan
- France
- Germany
- Netherlands
- Singapore
- Spain
- Finland
- Others

Pie chart values: 33%, 11%, 6%, 6%, 3%, 3%, 3%, 2%, 2%, 2%, 2%, 2%, 1%, 1%, 20%

- The geographic distribution of readers reflects *CDR*'s global reach, demonstrating that we are a **truly international journal** dedicated to removing barriers to scientific research and advancing cancer drug resistance globally.

III. Journal Metric

🔔 3.1 Scopus

CiteScore (CS) was introduced by Elsevier in December 2016 as an alternative to the Journal Citation Reports (JCR) impact factor (IF) calculated by Clarivate.

CiteScore 2022 counts the citations received in 2019-2022 to articles, reviews, conference papers, book chapters and data papers published in 2019-2022, and divides this by the number of publications published in 2019-2022.

CDR received a **5.5 in CiteScore 2022** and a **6.3** in the December 2023 update of **CiteScore Tracker 2023**.

OAE Publishing Inc.

Cancer Drug Resistance

Scopus coverage years: from 2018 to Present

Publisher: OAE Publishing Inc.

E-ISSN: 2578-532X

Subject area: (Medicine: Pharmacology (medical))   (Biochemistry, Genetics and Molecular Biology: Cancer Research)

Source type: Journal

[View all documents >]   [Set document alert]   💾 Save to source list

---

CiteScore | CiteScore rank & trend | Scopus content coverage

CiteScore 2022 ⌄

$$5.5 = \frac{1{,}590 \text{ Citations } 2019 - 2022}{288 \text{ Documents } 2019 - 2022}$$

Calculated on 05 May, 2023

CiteScoreTracker 2023 ⓘ

$$6.3 = \frac{1{,}513 \text{ Citations to date}}{241 \text{ Documents to date}}$$

Last updated on 05 December, 2023 • Updated monthly

CiteScore rank 2022 ⓘ

Category	Rank	Percentile
Medicine └ Pharmacology (medical)	#80/260	69th
Biochemistry, Genetics and Molecular Biology └ Cancer Research	#113/214	47th

3.2 Citations and 2022 Impact Factor

As announced by Clarivate Analytics in the Journal Citation Reports (JCR), Journal of the *Cancer Drug Resistance* (**CDR**) has achieved its first **Impact Factor of 3.7** in June, 2023.

∗Citable Items: classed as "original article", "review" or "proceedings paper" in the Web of Science (WoS) database; other items like editorials, corrections, notes, opinion, retractions and discussions are excluded.

2022 Citations of Articles published in 2020 & 2021

Year	Total Publication (Citable Items)	Times Cited in 2022
2020	68	224
2021	62	260

■ Total Publication (Citable Items)   ■ Times Cited in 2022

IV. Acknowledgement

4.1 Editorial Board Acknowledgement

4.2 Junior Editorial Board Acknowledgement

4.3 Guest Editors Acknowledgement

4.4 Reviewers Acknowledgement

4.1 Editorial Board Acknowledgement

79 Editors in 15 Countries/Region

USA (33)

Italy (10)

China (8)

Australia (2)

Switzerland (2)

Singapore (2)

France (1)

Denmark (1)

Portugal (1)

Netherlands (6)

United Kingdom (5)

Germany (4)

Japan (2)

Israel (1)

Belgium (1)

Editor-in-Chief

Godefridus J. Peters

As the curtain falls on another productive year, it is both a privilege and a pleasure to extend our heartfelt gratitude to the esteemed members of our Editorial Board across our journal *CDR*.

The multifaceted roles you have undertaken—ranging from meticulous manuscript reviews and stringent quality control to the conception and curation of special issues—have significantly enriched the scholarly discourse within our respective fields.

Your contributions not only uphold the rigorous standards of academic publishing but also foster a vibrant intellectual community.

Current Editorial Board:
https://www.oaepublish.com/cdr/editor

Special Issues: A Showcase of Expertise and Innovation

This year, we are particularly grateful to our Academic Editors for their exceptional efforts in curating and creating special issues. Their vision, expertise, and innovative approach have provided our readership with invaluable insights and perspectives, thereby elevating the depth and breadth of discussions within our journals. They are:

Paolo E. Porporato
Jacqueline Cloos
Enrico Mini
Hang Fai Kwok
Michael M. Gottesman
Robert W. Robey
Suresh V. Ambudkar
Thomas Efferth
Sanjay Gupta
Shashank Kumar
Paola Perego
Stergios Boussios
José Rueff
Wafik S. El-Deiry
Elisa Giovannetti
Mario Cioce
Gautam Sethi
Hailin Tang
Chiara Riganti
Bernhard Biersack (Junior Editorial Board)

4.2 Junior Editorial Board Acknowledgement

The meticulous process of peer review is central to upholding the quality and credibility of academic journals. It demands not only expertise but also a profound commitment to advancing knowledge within one's field.

Our Junior Editorial Board members have shown exemplary dedication and expertise in their roles as reviewers. We extend our gratitude for their valuable role as reviewers. These skilled early-career researchers are a valuable asset to our reviewing team.
They were:

Bernhard Biersack	Ilana Chefetz	Hexin Chen	Ivy Chung
Alessandra Ferraresi	Natalie R. Gassman	Xin Hong	Sachi Horibata
Weiwen Long	Elena Mariotto	Chiara Martinelli	Hyllana C. D. Medeiros
Faisal Raza	Iris C. Salaroglio	Santosh Singh	Giandomenico Roviello
Abhishek Tyagi	Cristina Xavier	Yanlin Yu	Giorgia Zadra
Xiangxuan Zhao	Quazi T.H. Shubhra	Ravi P. Sahu	Ling Wang
Jianye Zhang	Wei Zhao	Ying Shen	Jingya Wang
Parvez Khan	Jingquan Wang	Fei Zhou	

*Listed in no particular order

4.3 Guest Editors Acknowledgement

We would like to extend our sincere appreciation to the distinguished guest editors who have contributed significantly to the success and impact of our journal on cancer drug resistance. Their expertise, dedication, and collaborative efforts have played a pivotal role in curating high-quality content, fostering academic discourse, and advancing the field. We are deeply grateful for their commitment and look forward to continued collaboration in the pursuit of excellence in scientific research and publication.

They are:

Michael Lahn
Jordi Rodon
Hendrik Tobias Arkenau
Jong Seung Kim
Guru P. Sonpavde
Joseph Ciccolini
Shi-Yong Sun
Gen Sheng Wu
Yong Teng
Steven T. Rosen
Tanya Siddiqi
Alexey Danilov
Lily Wang
Xin Chen

4.4 Reviewers Acknowledgement

OAE Publishing Inc.

In the intricate tapestry of academic publishing, reviewers serve as the unsung heroes, diligently ensuring the rigor, clarity, and integrity of scholarly work. The reviewer community at *Cancer Drug Resistance (CDR)* continues to expand, enriched by the addition of highly qualified early-career researchers. Their insights and critiques play a critical role in ensuring that journals publish high-quality research and provide feedback to authors during the peer review process.

We are very grateful to our reviewers over the past year who have been willing to invest their time and expertise to ensure that our journal remains at the forefront of scholarly discourse.

For the list of 2023 reviewers click:

Reviewer Acknowledgement for 2023
(https://www.oaepublish.com/news/cdr.682)

OAE Publishing Inc.

Contact us

🐦 @cdrjournal

💬 Cancer Drug Resist

in **Louise Pan**

  Susan Song

✉ **editorial@cdrjournal.com**

🏠 https://www.oaepublish.com/cdr